Novonesis has closed its purchase of MicroBioGen, bringing the Australian biotech’s yeast-breeding platform in house to speed up biosolutions for several industries.
In the first half of 2026, the FDA cleared 22 new cancer treatments. AstraZeneca topped the sponsor list, and pembrolizumab became the backbone of new drug combinations. The focus is shifting to pairing proven drugs.
Novo Nordisk will pay $2.6 billion for rights to Hengrui Pharma’s HRS-1596, a once-weekly oral GLP-1/GIP dual agonist now in Phase 1 trials for type 2 diabetes and weight management.
DARPA has handed Systems Planning and Analysis a $10.9 million contract to run its biotechnology projects with AI support through 2031. This marks a sharp turn toward AI-driven oversight in U.S. defense biotech.
GenoMethods explains biotechnology from method to medicine to market, connecting scientific evidence, clinical development, companies and the technologies shaping future health.
